TRAVERSE Trial Summary The abstract highlights the findings of the TRAVERSE trial, which aimed to assess the cardiovascular safety of testosterone-replacement therapy in middle-aged and older men with hypogonadism. The trial sought to determine whether testosterone replacement therapy in this population increased the risk of cardiovascular events. The inclusion criteria for participants required them to […]
Category: Endocrinology
AMPLITUDE-O Trial: CV and Renal Outcomes with Efpeglenatide
2021 AMPLITUDE-O TRIAL M Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes international, randomized, controlled trial Objective: To evaluate efpeglenatide in participants with type 2 diabetes and either a history of cardiovascular disease or current kidney disease 4076 patients Inclusion criteria: Participants ≥18 years of age with type 2 diabetes mellitus and history […]
ADVANCE Trial Summary: Intensive Glucose Control in Diabetes Type 2
2008 ADVANCE TRIAL Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Multicenter, factorial, randomized trial Objective: To evaluate vascular effects of intensive glycemic therapy targeting a HbA1c <6.5% in patients with type II diabetes 11,140 Patients with DMII diagnosed at ≥30 years of age and hx of major macrovascular or […]
ACCORD Trial: Intensive Glucose Lowering in DM2
ACCORD: Effects of Intensive Glucose Lowering in Type 2 Diabetes Multicenter, double-blinded, two-by-two factorial, randomized controlled trial Objective: To assess if intensive glycemic control targeting a HbA1c <6% versus standard glycemic control targeting a HbA1c 7-7.9% reduce the risk of CV events in patients with type II diabetes. Patients with type II diabetes mellitus 7.9% […]
ACCORD BP Trial Summary: Intensive BP Control in Type 2 Diabetes
2010 ACCORD BP TRIAL Effects of intensive blood-pressure control in type 2 diabetes mellitus Multicenter, randomized, controlled, open-label trial Objective: In patients with T2DM at high risk for CV events, does intensive BP control (SBP <120 mmHg) reduce rates of nonfatal MI, nonfatal stroke, or CV mortality when compared to standard BP control (SBP <140 […]